Contrasting Marpai (NASDAQ:MRAI) & Global Cord Blood (NYSE:CORBF)

Marpai (NASDAQ:MRAI) and Global Cord Blood (NYSE:CORBF) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares Marpai and Global Cord Blood’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marpai	-77.38%	N/A	-75.05%
Global Cord Blood	N/A	N/A	N/A

Institutional and Insider Ownership

49.8% of Marpai shares are owned by institutional investors. 61.3% of Marpai shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Marpai and Global Cord Blood’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$37.15 million	0.61	-$28.75 million	($4.41)	-0.50
Global Cord Blood	$196.12 million	N/A	$79.04 million	N/A	N/A

Global Cord Blood has higher revenue and earnings than Marpai.

Volatility & Risk

Marpai has a beta of 5.41, suggesting that its share price is 441% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Marpai and Global Cord Blood, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0	0	1	0	3.00
Global Cord Blood	0	0	0	0	N/A

Marpai currently has a consensus price target of $6.00, indicating a potential upside of 174.60%. Given Marpai’s higher possible upside, equities analysts plainly believe Marpai is more favorable than Global Cord Blood.

Summary

Marpai beats Global Cord Blood on 5 of the 9 factors compared between the two stocks.

About Marpai

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, bill review and cost containment services. It also develops artificial intelligence and healthcare technology. Marpai, Inc. was incorporated in 2021 and is headquartered in New York, New York.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.